CellCept, Mycophenolate Newswire

CellCept, Mycophenolate Newswire

Comprehensive Real-Time News Feed for CellCept, Mycophenolate (generic).

Results 1 - 20 of 90 in CellCept, Mycophenolate (generic)

  1. Case report: subacute tetraplegia in an immunocompromised patientRead the original story w/Photo

    Thursday Feb 9 | BioMed Central

    Clinical reasoning in Neurology is based on general associations which help to deduce the site of the lesion. However, even "golden principles" may occasionally be deceptive.

    Comment?

  2. The effect of calcineurin inhibitors in the induction and maintenance ...Read the original story

    Wednesday Feb 8 | CiteULike

    The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. To evaluate the efficacy and safety of the calcineurin inhibitors cyclosporine and tacrolimus in the induction and maintenance treatment of lupus nephritis .

    Comment?

  3. Variation in prescribing practices for pediatric atopic dermatitisRead the original story w/Photo

    Monday Feb 6 | PhysOrg Weblog

    Prescribing practices vary among U.S. and Canadian physicians treating severe childhood atopic dermatitis , according to a study published in the February issue of the Journal of the American Academy of Dermatology . Christine R. Totri, M.D., from SUNY Downstate Medical Center in Brooklyn, N.Y., and colleagues surveyed systemic agent prescribing practices for severe childhood AD among clinicians in the United States and Canada in an online multiple-response survey.

    Comment?

  4. Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis.Read the original story

    Thursday Feb 2 | CiteULike

    Variability in the management of glomerulonephritis may negatively impact efficacy and safety. However, there are little/no data on actual variability in the treatment of minimal change disease /focal segmental glomerulosclerosis in adults.

    Comment?

  5. Aurinia Selects Worldwide Clinical Trials As Its CRO For Phase 3 Lupus Nephritis TrialRead the original story

    Thursday Jan 26 | BioSpace

    Aurinia Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has selected Worldwide Clinical Trials as its Clinical Research Organization for the AURORA Phase 3 study of volcosporin for the treatment of active lupus nephritis . Selecting a CRO for AURORA is a key milestone for Aurinia following our successful end-of-Phase 2 meeting with the U.S. Food & Drug Administration Division of Pulmonary, Allergy and Rheumatology Products.

    Comment?

  6. Lupus Nephritis: A Different Disease in European Patients?Read the original story

    Wednesday Jan 25 | CiteULike

    Lupus nephritis is still associated with significant mortality and substantial risk of progression to end-stage renal failure. Its outcome is related to the class and severity of LN and response to treatment, and it is poorer in patients with renal relapses.

    Comment?

  7. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current...Read the original story

    Wednesday Jan 25 | CiteULike

    Neuropsychiatric systemic lupus erythematosus is a generic definition referring to a series of neurological and psychiatric symptoms directly related to systemic lupus erythematosus . NPSLE includes heterogeneous and rare neuropsychiatric manifestations involving both the central and peripheral nervous system.

    Comment?

  8. A comprehensive evaluation for the treatment of lupus nephritis.Read the original story

    Tuesday Jan 24 | CiteULike

    Systemic lupus is the prototypic human autoimmune disease. It is a kaleidoscope of autoreactivities, with clear indications of both a genetic and environmental basis.

    Comment?

  9. Aurinia Pharmeceuticals: Opportunity In FocusRead the original story w/Photo

    Jan 18, 2017 | Seeking Alpha

    The company is likely to run up in price ahead of the release of the company's 48-week data, which is related to the company's proof of concept study. The evidence that I provide can be placed into 5 categories: the company's science, the capital structure, the current valuation, price action, and the risk vs. reward.

    Comment?

  10. Corbus Release: Pharma Receives Orphan Designation For JBT-101 For...Read the original story

    Jan 16, 2017 | BioSpace

    "We are pleased to receive our second Orphan Designation in the EU for JBT-101. We look forward to the continued advancement of our global clinical and regulatory development strategy for JBT-101 for the treatment of serious and rare inflammatory and fibrotic diseases," stated Yuval Cohen, Ph.D., Chief Executive Officer.

    Comment?

  11. A severe case of visceral leishmaniasis and liposomal amphotericin B...Read the original story w/Photo

    Jan 16, 2017 | BioMed Central

    Visceral leishmaniasis is a protozoan disease, which is responsible for 200.000-400.000 yearly infections worldwide. If left untreated, the fatality rate can be as high as 100% within 2 years.

    Comment?

  12. Consensus Conference on Clinical Practice in Chronic GVHD:...Read the original story

    Jan 13, 2017 | CiteULike

    Biology of Blood and Marrow Transplantation , Vol. 17, No. 1. , pp. 1-17, doi:10.1016/j.bbmt.2010.05.011 Steroid refractory chronic graft-versus-host disease is associated with a significant morbidity and mortality.

    Comment?

  13. Lupus Nephritis Market- Positive Long-Term Growth Outlook 2016 - 2023Read the original story w/Photo

    Jan 12, 2017 | SBWire

    Global Lupus Nephritis Market: Overview The growing prevalence of lupus nephritis and awareness among patients have propelled the growth of the global lupus nephritis market. Rise in number of clinical trials conducted by key market players and the launch of new biologic drugs will also augment the growth of the global lupus nephritis market.

    Comment?

  14. Moderator's view: Cyclophosphamide in lupus nephritis.Read the original story

    Jan 12, 2017 | CiteULike

    Mycophenolate mofetil was recently accepted as the effective induction treatment of lupus nephritis, with the potential to replace cyclophosphamide or at least expand our therapeutic armamentarium in patients with this lifelong disease often requiring repeated induction treatment of its relapses. Compared with cyclophosphamide, mycophenolate may be more effective in black patients, and the risk of gonadotoxicity may be significantly lower in mycophenolate-treated subjects.

    Comment?

  15. Should patients older than 65 years be offered a second kidney transplant?Read the original story w/Photo

    Jan 11, 2017 | BioMed Central

    Age and number of recipients in need of kidney re-transplantation are increasing. Re-transplantation practices and outcomes in elderly recipients are not previously explored.

    Comment?

  16. JPM17: Aurinia??'s CEO on a Mission to Improve the Way Lupus Nephritis is TreatedRead the original story

    Jan 9, 2017 | BioSpace

    January 10, 2017 By Renee Morad , BioSpace.com Breaking News Staff SAN FRANCISCO -Patients diagnosed with lupus nephritis , an often overlooked but serious condition, suffer from inflammation of the kidney that is caused by lupus erythematosus , also known as lupus for short. The overwhelming majority of patients are women - and many are of childbearing age, which makes high-steroid treatment options counterintuitive for those hoping to have children in the future.

    Comment?

  17. Market Attractiveness Analysis - Organ Transplant Immunosuppressant...Read the original story w/Photo

    Jan 6, 2017 | SBWire

    The global organ transplant immunosuppressant drugs market exhibits a highly consolidated vendor landscape. The top five companies held more than 90% of the market in 2014.

    Comment?

  18. Column 8Read the original story w/Photo

    Dec 18, 2016 | Sydney Morning Herald

    "Having conducted a quick survey I've concluded the general consensus is that watching Mr Obeid sitting in his jail cell would be infinitely preferable to the current choice on free-to-air television. Eddie-cam: taxpayers would be grateful.

    Comment?

  19. Management of Membranous Nephropathy in Asia.Read the original story

    Dec 14, 2016 | CiteULike

    Membranous nephropathy is the most common cause of nephrotic syndrome in adults, accounting for about 20.0% of all NS cases. With an increasing prevalence, especially in the elderly, it has received great attention in Asia.

    Comment?

  20. Lupus Nephritis in Asia: Clinical Features and Management.Read the original story

    Dec 14, 2016 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Lupus nephritis is a common and severe organ involvement manifesting itself in systemic lupus erythematosus .

    Comment?